Abstract P5-12-10: Tamoxifen versus anastrozole as adjuvant therapy in early stage breast cancer in premenopausal women on ovarian function suppression: A meta-analysis of randomized clinical trials

2020 ◽  
Author(s):  
Shima Sidahmed ◽  
Ahmed Abdalla ◽  
Babikir Kheiri ◽  
Ghassan Bachuwa
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Adjuvant Therapy ◽  
Randomized Clinical Trials ◽  
Ovarian Function ◽  
Early Stage ◽  
Meta Analysis ◽  
Premenopausal Women ◽  
Early Stage Breast Cancer ◽  
Ovarian Function Suppression

Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer

2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Matteo Lambertini ◽  
Lucia Del Mastro ◽  
Giulia Viglietti ◽  
Noam F. Pondé ◽  
Cinzia Solinas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Function ◽  
Early Stage ◽  
Premenopausal Women ◽  
Early Stage Breast Cancer ◽  
Ovarian Function Suppression

The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 1050-1050
Author(s):  
Rodrigo Ramella Munhoz ◽  
Allan Andresson Lima Pereira ◽  
Andre Deeke Sasse ◽  
Paulo Marcelo Hoff ◽  
Tiffany A. Traina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Ovarian Function ◽  
Early Stage ◽  
Meta Analysis ◽  
Premenopausal Women ◽  
Early Stage Breast Cancer ◽  
Lhrh Agonists ◽  
Function Preservation

Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 513-513 ◽  
Author(s):  
Walter Gregory ◽  
Helen Marshall ◽  
Richard Bell ◽  
David A. Cameron ◽  
Robert Edward Coleman
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Postmenopausal Women ◽  
Risk Reduction ◽  
Early Stage ◽  
Meta Analysis ◽  
Menopausal Status ◽  
Premenopausal Women ◽  
Early Stage Breast Cancer ◽  
Sensitivity Analyses

513 Background: A number of groups have now reported results of randomised trials of adjuvant zoledronic acid (ZOL) for women with early stage breast cancer. Following an interaction effect observed in the AZURE trial, where postmenopausal women appeared to benefit from ZOL, we performed a meta-analysis, from both publications and presented data, of the most recent results from these trials. We also looked at recently reported large studies of clodronate and ibandronate in older or postmenopausal women to further examine this hypothesis. Methods: DFS data from 8735 women in 7 trials (AZURE, ABCSG-12, ZO-FAST, Z-FAST, EZO-FAST, NSABP-B34, GAIN) that included a randomization to ZOL vs. control or clodronate/ibandronate vs. control were examined. Median follow-up was 5 years. 14% of women experienced a DFS event. The ABCSG-12 study was included since, although it included only premenopausal women, they were all treated with goserelin, effectively rendering them postmenopausal, prior to and during treatment with ZOL. We analysed the subgroup of women aged ≥50 in the NSABP-B34 study in the absence of information on menopausal status, and included only postmenopausal women from the AZURE and GAIN trials. Sensitivity analyses confirmed that exclusion of some older, small, clodronate studies that lacked DFS data, or failed to report by age or menopausal status would be unlikely to alter these findings. Results: For the 5 ZOL studies alone, there was a very substantial and highly significant DFS benefit for ZOL, 2P=.0006, with a hazard ratio of 0.76, and therefore a DFS risk reduction of 24% (95% CI 11%-35%). The results were, in the main, extremely consistent, with the exception of the very small E-ZO-FAST study, which had only 30 events. The risk reduction lessened to 18% (95% CI 8%-26%) when adding in the clodronate and ibandronate studies, but the result remained highly significant (2P=.00075). Conclusions: These meta-analysis results, including more than 8000 women in a range of studies, now provide strong evidence that ZOL is an effective adjuvant treatment for postmenopausal women with early stage breast cancer, and that the treatment benefits are substantial.

scholarly journals Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis

2017 ◽  
Vol 31 (1) ◽  
pp. 515-520 ◽  
Author(s):  
Majid Davari ◽  
Bahman Amani ◽  
Fariborz Mokarian ◽  
Mohsen Hoseini ◽  
Arash Akbarzadeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adjuvant Therapy ◽  
Early Stage ◽  
Meta Analysis ◽  
Early Stage Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document